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DESCRIPTION
DW was a born in China with complete unilateral cleft lip and palate.
She was placed in an orphanage shortly after birth. At 19 months of
age, a family in the United States adopted her, and shortly thereafter,
she underwent uneventful cleft lip repair. At 20 months of age she had a
positive Mantoux Puriﬁed Protein Derivative (PPD) test and was begun
on Isoniazid monotherapy for possible latent tuberculosis. She was
brought to the operating room a second time at 22 months of age for a
palatoplasty. She was noted to have abnormal bleeding intraoperatively.
Her platelet count was found to be 43,000 per microliter; she was
diagnosed as having drug-induced thrombocytopenia (DITP). Her
palatoplasty was completed, albeit with less extensive dissection that
NEXTmightotherwisehavebeenperformed.ShewasadmittedtothePediatric
Intensive Care Unit, intubated and had transfusion with platelets and
packed red blood cells. She did well with clinical resolution of hem-
orrhage and was extubated. She postoperatively developed a palatal
ﬁstula. In the perioperative period her Isoniazid therapy was held, and
herplateletcountrecoveredto203,000permicroliter.Shesubsequently
hadapositiveantigentestformycobacteria,conﬁrmingalatenttubercu-
losis infection. She was begun on Isoniazid once again. She completed
9-month course of Isoniazid, during which time her platelet count
reached a second nadir of 107,000 per microliter; she had no further
episodes of abnormal bleeding. At 28 months of age, after completion
of her antitubercular therapy, her platelet count recovered to 363,000
permicroliter.Sheunderwentrevisionpalatoplasty,uneventfully,which
was successful in closing her palatal ﬁstula.
NEXT BACKQUESTIONS
1. How should a surgeon evaluate a possible case of DITP?
2. Where can a surgeon ﬁnd a database of DITP reports?
3. What is the process for reporting a case of DITP?
NEXT BACKDISCUSSION
The most widely accepted model for DITP postulates preexisting antibodies
with low afﬁnity to platelet epitopes; in the presence of an inducing drug,
these are converted to high afﬁnity to this epitope.1-6
The University of Oklahoma Health Sciences Center maintains a Web-
based database of case reports of DITP; this database lists 1299 single patient
reports, and 143 group series reports collected up to October 20, 2010.7 There
is a single case report by Hansen in 1961 of Isoniazid causing DITP.8
Georgeetal9 publishedasystemicreviewofpublishedcasereportsofDITP.
In this review, they set forth criteria for evaluation of published patient data:
1. Drug administration preceded thrombocytopenia; recovery from throm-
bocytopenia completed and sustained after drug discontinued.
2. Other drugs administered prior to thrombocytopenia were continued or
reintroduced after discontinuation of the suspected drug.
3. Other etiologies of thrombocytopenia excluded.
4. Reexposure to the drug resulted in recurrent thrombocytopenia.
On the basis of these criteria, they stratiﬁed studies into the following levels
of evidence:
1. Deﬁnite: all 4 criteria met.
2. Probable: criteria 1-3 met.
3. Possible: criterion 1 met.
George et al9 then tallied the case reports and found 48 drugs with level 1,
or deﬁnite evidence, and 15 drugs with only level 2 or probable evidence of
causing thrombocytopenia. Hansen’s 1961 report of DITP from Isoniazid met
the criteria for level 1 or deﬁnite evidence for DITP.8 The 21 drugs with 5 or
more reports that meet either deﬁnite or probable evidence are presented in
tabular form (Table 1).
The patient presented in this case report shows level 1 evidence of DITP
based on the criteria described by George et al:
1. Administration of Isoniazid preceded the episode of thrombocytopenia,
and recovery was sustained after withdrawal of the drug, both initially,
and after reintroduction.
2. There were no other drugs, other than the anesthetic agents and prophy-
lactic antibiotics administered during the surgical procedure. The time
course of the bleeding episode makes these very unlikely as causative
agents for DITP.
NEXT BACK3. The child did not show hemolytic anemia, nor progress to uremia or
neurologic sequella, does not meet the diagnostic criteria of thrombotic
thrombocytopenicpurpura-hemolyticuremicsyndrome.10Likewise,she
showed resolution of her thrombocytopenia, so diagnosis of idiopathic
thrombocytopenia purpura would not be accurate.11
4. Her Platelet count dropped again after resumption of Isoniazid, albeit
without clinical consequences.
George et al offers the following a protocol for evaluation of patients with
suspected DITP:
1. Determine the probability for a causal relation of the suspected drug to
the occurrence of thrombocytopenia using the clinical criteria presented
in Table 1.
2. Determine previously published experience.
3. ChecktheDITPdatabase(www.ouhsc.edu/platelets)forpreviouslypub-
lished reports describing the suspected drug. Are there previous reports
with deﬁnite or probable evidence for a causal relation of the suspected
drug and thrombocytopenia?
4. Determine the presence of drug-dependent antiplatelet antibodies to
conﬁrm the etiologic role of the drug that is suspected as the cause of
thrombocytopenia.
5. Ifthedrugisconﬁrmedasthecauseofthrombocytopeniabyclinicalcri-
teria and/or by demonstration of drug-dependent antiplatelet antibodies,
report the patient to the Food and Drug Administration Adverse Event
Reporting System by using www.fda.gov/medwatch/.
6. If there are no or few published case reports with deﬁnite or probable
clinical evidence for a causal role of the drug with thrombocytopenia,
publish your experience.
This is the second case report of Isoniazid-induced thrombocytopenia in
50years;itseemsunlikelythatanothercasewillbeseenbyapracticingplastic
surgeon with any frequency. It is instructive, however, to review the process
for evaluation of possible cases of DITP, as well as the protocol for reporting
index cases.
NEXT BACKTable 1. Drugslikelytocausethrombocytopenia (deﬁniteorprobableevidence), after
George et al9
Number of Reports
Drug (Brand Name) Deﬁnite Evidence Probable Evidence
Abciximab (ReoPro) 6 7
Acetaminophen (Tylenol, Panadol) 3 4
Carbamezapine (Tegretol) 0 10
Chlorpropamide (Diabinese) 0 5
Cimetidine (Tagamet) 1 5
Danazol (Danocrine) 3 4
Diclofenac (Cataﬂam and Voltaren) 2 3
Efalizumab (Raptiva) 0 6
Eptiﬁbatide (Integrilin) 2 7
Gold (Ridaura, Solganal) 0 11
Hydrochlorothiazide (Diuril) 0 5
Interferon-α (Roferon-A) 1 6
Methyldopa (Aldomet) 3 3
Nalidixic Acid (NegGram) 1 5
Quinidine (Quinaglute, Cardioquin) 26 32
Quinine (Quinamm, Quindan) 14 10
Ranitidine (Zantac) 0 5
Rifampin (Rifadin, Rimactane) 5 5
Tiroﬁban (Aggrestat) 2 6
Trimethoprim/sulfamethoxazole (Bactrim, Septra) 3 12
Vancomycin (Vancoled) 3 4
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